← Back to Search

Other

ZN-e4 for Non-Small Cell Lung Cancer

Phase 1
Waitlist Available
Research Sponsored by Zeno Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, approximately 2 years
Awards & highlights

Study Summary

This trial is testing a new drug for people with advanced lung cancer who have a specific gene mutation. The goal is to see if the drug is safe and works against the cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, approximately 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, approximately 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Observed dose limiting toxicities
Secondary outcome measures
Safety and tolerability as measured by incidence of treatment emergent adverse events

Trial Design

2Treatment groups
Experimental Treatment
Group I: Phase 2Experimental Treatment1 Intervention
MTD/RP2D in subjects: Cohort 1: with T790M mutation in epidermal growth factor receptor (EGFR) gene, and are osimertinib naïve. Cohort 2: EGFRm amenable to EGFR inhibitor therapy (eg, exon 19 del, L858R) and who have never been treated with EGFRis.
Group II: Phase 1Experimental Treatment1 Intervention
Up to 9 sequential dose escalation cohorts to determine maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is identified.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ZN-e4
2018
Completed Phase 1
~40

Find a Location

Who is running the clinical trial?

Zeno Pharmaceuticals, Inc.Lead Sponsor
Zeno PharmaceuticalsStudy DirectorZeno Pharmaceuticals

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still vacancies for participants in this experiment?

"Based on the information contained within clinicaltrials.gov, this medical trial is no longer actively accepting participants. Initially posted in April of 2018 and last edited November 14th 2022, it has since been superseded by 1361 other studies that are currently recruiting individuals."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer
2018. "A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03446417.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top